Literature DB >> 4943273

Sensitive procedure for detecting residual viable virus in inactivated rabies vaccine.

J R Mitchell, R E Everest, G R Anderson.   

Abstract

A procedure for testing inactivated rabies vaccines of tissue culture origin for residual viable virus is reported in which the vaccine to be tested is passed in primary hamster kidney cell culture (PHK) before mouse inoculation. In preliminary experiments, titrations of rabies virus in which each dilution was passed in PHK before inoculating mice yielded titers 100 to 10,000 times higher than the titers obtained for the same virus by direct mouse inoculation. This rabies virus amplification procedure was evaluated by testing 18 lots of inactivated rabies vaccine of tissue culture origin. No viable virus was found in these vaccine lots when tested by direct intracerebral inoculation of mice. Eight of these 18 lots were found to contain viable virus, however, when tested by passage in PHK cell culture. The significance of low levels of viable virus in rabies vaccines is discussed. It is recommended that the amplification procedure described in this report be used in the safety testing of rabies vaccines of tissue culture origin and that it be evaluated for use in testing other rabies vaccines of low tissue content.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4943273      PMCID: PMC376370          DOI: 10.1128/am.22.4.600-603.1971

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  1 in total

1.  Growth of rabies virus in non-nervous tissue culture.

Authors:  R E KISSLING
Journal:  Proc Soc Exp Biol Med       Date:  1958-06
  1 in total
  2 in total

1.  Rabies vaccines and interferon.

Authors:  G S Turner
Journal:  J Hyg (Lond)       Date:  1972-09

2.  Sensitivity of bhk-21 cells supplemented with diethylaminoethyl-dextran for detection of street rabies virus in saliva samples.

Authors:  O P Larghi; A E Nebel; L Lazaro; V L Savy
Journal:  J Clin Microbiol       Date:  1975-03       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.